Terns Pharmaceuticals, Inc. Common Stock (TERN) Stock Price

TERNStock
$0.00−30.12%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta2.39

TERN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)541.28%
Price vs S&P 500 (4W)-7.06%
VGM Score39.02

TERN Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2025-$0.28-$0.24+13.60%(+$0.04)
Q3 2025-$0.30-$0.27+8.93%(+$0.03)
Q2 2025-$0.29-$0.26+9.09%(+$0.03)
Q1 2025-$0.27-$0.26+3.79%(+$0.01)

TERN Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.47
3.47
3.47
3.47

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TERNTerns Pharmaceuticals, Inc. Common Stock
—FB—-100.0%——$0.00
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Terns Pharmaceuticals, Inc. Common Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company's pipeline includes multiple candidates, including TERN-701, TERN-601, TERN-501, and TERN-800, designed for both single-agent and combination therapy approaches to address significant unmet clinical needs in liver disease treatment.